| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | K Shannon | |
| C M Tanner | |||
| G F Wooten | |||
| P Huang | |||
| B Ravina | |||
| K Kieburtz | |||
| B C Tilley | |||
| NET-PD Investigators | |||
| Y Y Palesch | |||
| J J Elm | |||
| G C Goetz | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 628-633 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | |
| P478 | volume | 66 |
| Q30407150 | A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results |
| Q36576472 | Advances in designs for Alzheimer's disease clinical trials. |
| Q46823146 | Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
| Q55112408 | Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. |
| Q51158231 | Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials? |
| Q42616360 | Combination therapies for traumatic brain injury: prospective considerations |
| Q37675595 | Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial |
| Q24193947 | Creatine for Parkinson's disease |
| Q53220635 | Design of phase II ALS clinical trials. |
| Q37622166 | Developmental susceptibility of neurons to transient tetrahydrobiopterin insufficiency and antenatal hypoxia-ischemia in fetal rabbits |
| Q30407589 | Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial |
| Q33964112 | Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial |
| Q40494176 | Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study |
| Q28284355 | Huntington's disease |
| Q30431912 | Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease |
| Q34658560 | Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial |
| Q26995786 | Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments |
| Q29616300 | Neuroinflammation in Parkinson's disease: a target for neuroprotection? |
| Q37203405 | Neuroprotection in Parkinson's disease: myth or reality? |
| Q50073420 | New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States. |
| Q37172826 | Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy |
| Q38056875 | Overcoming obstacles in Parkinson's disease |
| Q80970949 | Parkinson's disease |
| Q30357397 | Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. |
| Q34508143 | Seniors with Parkinson's disease: initial medical treatment |
| Q90597542 | Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study |
| Q91268058 | Statistical advances in clinical trials and clinical research |
| Q37161380 | Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans |
| Q45305395 | TRACK-HD: both promise and disappointment |
| Q37302453 | Targets for neuroprotection in Parkinson's disease |
| Q36264697 | The futility study--Progress over the last decade |
| Q38380170 | The promise of futility trials in neurological diseases. |
Search more.